Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: analysis of patients with double-refractory or early relapsed follicular lymphoma (FL), Journal of Clinical Oncology, vol.35, p.7502, 2017. ,
Response rate to lenalidomide plus rituximab (R2) as independent of number of prior lines of therapy: interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL, Journal of Clinical Oncology, vol.36, pp.715-716, 2018. ,
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs, Nature Structural & Molecular Biology, vol.21, pp.803-809, 2014. ,
Phase IIIB study of lenalidomide plus rituximab followed by maintenance in relapsed or refractory NHL: analysis of marginal zone lymphoma, Hematological Oncology, vol.35, 2017. ,
Ibrutinib interferes with the cell-mediated antitumor activities of therapeutic CD20 antibodies: implications for combination therapy, Haematologica, vol.100, pp.77-86, 2015. ,
, Lenalidomide Plus Rituximab Restores Immune Function in FL ª 2019 The Authors, British Journal of Haematology, vol.185, pp.240-253, 2019.
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells, New England Journal of Medicine, vol.351, pp.2159-2169, 2004. ,
Absolute lymphocyte count as a predictive factor for response to monoclonal anti-CD20 antibody therapy, Annals of Oncology, vol.14, pp.171-172, 2003. ,
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study, Blood, vol.123, pp.2944-2952, 2014. ,
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial, The Lancet. Oncology, vol.15, pp.1311-1318, 2014. ,
Follicular lymphoma: 2018 update on diagnosis and management, American Journal of Hematology, vol.93, pp.296-305, 2018. ,
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.), British Journal of Haematology, vol.164, pp.811-821, 2014. ,
Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab, Annals of Hematology, vol.93, pp.1879-1887, 2014. ,
, Impaired functional responses in follicular lymphoma CD8+TIM-3+ T lymphocytes following TCR engagement. Oncoimmunology, 5, p.1224044, 2016.
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL, Blood, vol.126, pp.779-789, 2015. ,
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity, British Journal of Haematology, vol.179, pp.399-409, 2017. ,
Influence of R-CHOP therapy on immune system restoration in patients with Bcell lymphoma, Oncology, vol.91, pp.302-310, 2016. ,
Ibrutinib in combination with anti-CD20-antibody negatively affects antibody dependent cellular cytotoxic (ADCC) on mantle cell lymphoma cell lines, not reversed by the addition of lenalidomide, Blood, vol.130, p.1266, 2017. ,
Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds, Blood, vol.126, pp.50-60, 2015. ,
Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance), Journal of Clinical Oncology, vol.33, pp.3635-3640, 2015. ,
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide, Leukemia, vol.26, pp.2326-2335, 2012. ,
A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma, Leukaemia & Lymphoma, vol.57, pp.880-887, 2016. ,
Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma, British Journal of Haematology, vol.178, pp.250-256, 2017. ,
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance), Annals of Oncology, vol.28, pp.2806-2812, 2017. ,
Lenalidomide treatment restores in vivo T cell activity in relapsed/refractory FL and DLBCL, New England Journal of Medicine, vol.130, pp.934-947, 2017. ,
Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas, American Journal of Hematology, vol.93, pp.1-3, 2018. ,
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry, The Lancet. Oncology, vol.16, pp.1111-1122, 2015. ,
Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project, Haematologica, vol.101, pp.1244-1250, 2016. ,
, Oncology, vol.18, pp.1209-1215, 2007.
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug, The Journal of Clinical Investigation, vol.118, pp.2427-2437, 2008. ,
Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy, Blood, vol.114, pp.4713-4720, 2009. ,
Progression-free survival shortens after each relapse in patients with follicular lymphoma treated in the rituximab era, Hematological Oncology, vol.35, pp.360-361, 2017. ,
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, Lancet, vol.381, pp.1203-1210, 2013. ,
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the, Fondazione Italiana Linfomi. Haematologica, vol.101, pp.196-199, 2016. ,
Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma, Blood Cancer Journal, vol.5, p.362, 2015. ,
Long term followup of the PRIMA Study: half of patients receiving rituximab maintenance, p.486, 2017. ,
Cause of death in follicular lymphoma in the rituximab era: a pooled analysis of French and US cohorts, Hematological Oncology, vol.35, pp.34-35, 2017. ,
Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma, Leukemia Research, vol.37, pp.1213-1215, 2013. ,
US lymphoid malignancy statistics by World Health Organization subtypes, CA: A Cancer Journal for Clinicians, vol.66, pp.443-459, 2016. ,
Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma, British Journal of Haematology, vol.165, pp.375-381, 2014. ,
NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment, Oncoimmunology, vol.7, p.1409322, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01780378
The promises and challenges of using gene mutations for patient stratification in follicular lymphoma, Blood, vol.130, pp.1491-1498, 2017. ,
lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells, Clinical Cancer Research, vol.14, pp.4650-4657, 2008. ,
The tumor microenvironment in follicular lymphoma, Clinical Advances in Hematology & Oncology: H&O, vol.10, pp.810-818, 2012. ,
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo, American Journal of Hematology, vol.84, pp.553-559, 2009. ,
, Lenalidomide Plus Rituximab Restores Immune Function in FL ª 2019 The Authors, British Journal of Haematology, vol.185, pp.240-253, 2019.